Evotec SE (EVO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.53 (-3.16% 1D, market cap $562.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVO ranks #343 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $556.7M) and STTK (Shattuck Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $574.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.7M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While EVO currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.61) forces dealer call-delta covering toward $4.29.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Evotec SE (EVO) dropped -3.16% to $1.53, trading at 7% of its 52-week range ($1.33 – $4.09). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Investing News Network report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026
Evotec’s latest announcement landed hard. Management cut its 2026 revenue and EBITDA guidance after partnership milestones slipped, then reported weaker Q2 2026 figures with a deeper net loss. For Evotec shareholders, th
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EVO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EVO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Evotec SE (EVO) ranks #343 by composite RQD confidence (47/100, grade D) and #429 by equity capitalization ($562.1M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with EVO at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EVO
ACTIVE
Evotec SE | D | 47/100 | — | — | — | -3.16% | $562.1M | Benchmark Subject |
| DRUG Bright Minds Biosciences Inc. | D | 46/100 | — | — | — | -3.02% | $556.7M | /drug-vs-evo → |
| STTK Shattuck Labs Inc. | E | 31/100 | — | — | -35.0% | -2.80% | $574.1M | /sttk-vs-evo → |
| NGNE Neurogene Inc. | D | 44/100 | — | — | -35.0% | -4.41% | $576.7M | /ngne-vs-evo → |
| PBYI Puma Biotechnology Inc | B- | 71/100 | 17.5x | 74.5% | 29.3% | -0.95% | $544.1M | /pbyi-vs-evo → |
Evotec SE (EVO) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $562.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.53 (-3.16% 1D, market cap $562.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVO ranks #343 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $556.7M) and STTK (Shattuck Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $574.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
EVO last traded at $1.53 (-3.16% on volume of 73,257 shares), positioning the stock -6.71% below its 50-day simple moving average ($1.64) and -39.04% below its 200-day simple moving average ($2.51). Across its 52-week range of $1.33 to $4.09, EVO sits at the 7.2% percentile with a 14-day RSI of 51.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($1.42 to $1.64).
Why EVO Stock dropped -3.16% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
The Roarable RQD rating is 47 / D, labeled "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars score as follows: Fundamental Cash Engine 12 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow 5 of 20 (institutional accumulation and options positioning); Insider Conviction 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 8 of 20 (Beta 1.0; sector sensitivity); Forensic Balance Sheet 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are institutional flow and macro fit, with the cash engine also scoring low because the source reports ROIC and FCF yield at 0%. The balance-sheet pillar is the relative strength, with an Altman Z of 2.5 and a Piotroski F of 6/9 per the RQD rating. Upside drivers would need to come from a shift in the cash-generation picture, which the source data does not show. Valuation cannot be assessed on earnings multiples because P/E, Forward P/E, and EV/EBITDA are not available in source data. The stock's 52-week range of $1.33 - $4.09 and current price of 1.58 place it in the lower portion of that range (per market data), which the rating interprets as distribution rather than accumulation.
Evotec SE (EVO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.6B. Product, customer, and revenue-model details are not available in source data.
The most prominent item is a headline reporting that Evotec appointed Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, flagged as a YELLOW light in the news wire. Other wire items are flagged as YELLOW (Yahoo! Finance Canada and ad-hoc-news.de headlines) or GREEN (a Siam report stating the ADR slipped 0.64% to $1.55 near the lower end of its range, and a report of a 9.51 percent weekly gain as results near). Several wire summaries are generic templates and contain no substantive fundamental content. The wire-flagged risk watch item is the ADR trading near the lower end of its range, per the Siam headline. Proprietary signals in the Butterfly Supply-Chain Graph are empty.
The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.
Real-time company headlines, analyst actions, and sector developments for Evotec SE (EVO) • Click "Debate This Headline" to argue it in the Roar Pit below
Investing News Network report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Welcome to the EVO (Evotec SE) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on EVO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Evotec SE expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on EVO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.58 (52-wk range $1.33 - $4.09), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).